Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors

Current Eye Research

Volumn 34, Issue 3, 2009, Pages 184-195

  Chen, June ^a   Lu, Ryan Ta ^a   Lai, Ronald ^a   Dinh, Tim ^a   Paul, David ^a   Venadas, Steven ^a   Wheeler, Larry A ^a  

^a ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Human peripheral blood T lymphoblasts; Intracellular calcium concentration ( Ca2+ i); Prostamide sensitive preparation; Prostanoid FP receptor

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; BIMATOPROST; CALCIUM; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN T RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOBLAST; T LYMPHOCYTE;

AMIDES; ANTIHYPERTENSIVE AGENTS; CALCIUM; CALCIUM SIGNALING; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CLOPROSTENOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOBLASTS; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 62249102141     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802669781     Document Type: Article

References (40)

1. Coleman RA, Smith WL, Narumiya S. VIII. International union of pharmacology. Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.
2. Schaaf TK, Hess H-J. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. J Med Chem. 1979;22:1340-1346.
3. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45:S337-S345.
4. Kozak KR, Crews BC, Morrow JD, Wang L-H, Ma YH, Weinander R, Jakobsson P-J, Marnett LJ. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877-44885.
5. Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, et al. Prostaglandin ethanolamides (prostamides): In vitro pharmacology and metabolism. J Pharmacol Exp Ther. 2004;309:745-757.
6. Woodward DF, Krauss AH-P, Chen J, Liang Y, Li C, Protzman CE, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305:772-785.
7. 2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res. 2005;80:135-145.
8. Chen J, Senior J, Marshall K, Abbas F, Dinh H, Dinh T, et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmacol. 2005;144:493-501.
9. Woodward DF, Krauss AH, Wang JW, Protzman CE, Nieves AL, Liang Y, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandinethanolamides) in the feline iris. Br J Pharmacol. 2007;150:342-352.
10. van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-1185.
11. 2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenousmouse, rat, and cloned human FP prostaglandin receptors. J Pharmacol Exp Ther. 2003;304:238-245.
12. 2α (FP) receptor. J Pharmacol Exp Ther. 1999;290:1278-1284.
13. Chen J, Dinh T, Woodward DF, Holland JM, Yuan Y-D, Lin T-H, Wheeler LA. Bimatoprost: Mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23:231-246.
14. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction. 3rd ed. New York: Lippincott-Raven; 1997:396-432.
15. Humphrey PPA, Barnard EA. International union of pharmacology. XIX. The IUPHAR receptor code: A proposal for an alphanumeric classification system. Pharmacol Rev. 1998;50:271-277.
16. 2α enhances phenotypic transformation of normal rat kidney fibroblasts. Am J Physiol Cell Physiol. 2005;289:C130-C137.
17. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol Rev. 1999;79:1193-1226.
18. Sarrazin P, Bkaily G, Hach́e R, Patry C, Dumais R, Rocha FAC, de Brum-Fernandes AJ. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids. 2001;64:203-210.
19. 2α in epithelial cell proliferation. J Clin Endocrinol Metab. 2003;88:1825-1832.
20. Gomez LA, Alekseev AE, Aleksandrova LA, Brady PA, Terzic A. Use of the MTT assay in adult ventricular cardiomyocytes to assess viability: Effects of adenosine and potassium on cellular survival. J Mol Cell Cardiol. 1997;29:1255-1266.
21. 2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. J Physiol. 1999;517(Part 1):95-107.
22. Parekh AB, Putney Jr JW. Store-operated calcium channels. Physiol Rev. 2005;85:757-810.
23. Parekh AB. On the activation mechanism of store-operated calcium channels. Pflugers Arch. 2006;453:303-331.
24. 2+ levels and proliferation in canine renal tubular cells. Basic Clin Pharmacol Toxicol. 2006;98:416-422.
25. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19-24.
26. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004;111:1658-1662.
27. Cooper DMF. Molecular and cellular requirements for the regulation of adenylate cyclases by calcium. Biochem Soc Trans. 2003;31:912-915.
28. Kamenetsky M, Middelhaufe S, Bank EM, Levin LR, Buck J, Steegborn C. Molecular details of cAMP generation in mammalian cells: A tale of two systems. J Mol Biol. 2006;362:623-639.
29. Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev. 1997;77:901-930.
30. Zhao X, Pearson KE, Stephan DA, Russell P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Invest Ophthamol Vis Sci. 2003;44:1945-1952.
31. Richter M, Krauss AH-P, Woodward DF, L̈utjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419-4426.
32. Samadfam R, Gallant MA, Miousse M-C, Parent J-L, de Brum-Fernandes AJ. Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. J Rheumatol. 2006;33:1167-1175.
33. 2α, latanoprost, and travoprost in isolated porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2006;47:295-298.
34. Sugimoto Y, Narumiya S, Ichikawa A. Distribution and function of prostanoid receptors: Studies from knockout mice. Prog Lipid Res. 2000;39:289-314.
35. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46:4159-4163.
36. Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci. 2005;46:4571-4577.
37. Rao GK, Kaminski NE. Cannabinoid-mediated elevation of intracellular calcium:Astructure-activity relationship. J Pharmacol Exp Ther. 2006;317:820-829.
38. Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of prostaglandin analogues on prostanoid EP1, EP2 , and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47:3395-3399.
39. Hartke JR, Lundy MW. Bone anabolic therapy with selective prostaglandin analogs. J Musculoskel Neuron Interact. 2001;2:25-31.
40. Girard B, Lelievre V, Braas KM, Razinia T, Vizzard MA, Ioffe Y, et al. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAPdeficient mice. J Neurochem. 2006;99:499-513.